La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The company has several product candidates in development, including LJPC-501, the company’s proprietary formulation of angiotensin II, a naturally-occurring regulator of blood pressure, and LJPC-401, its novel formulation of hepcidin, an endogenous peptide hormone that controls and regulates iron metabolism. For more information, visit the company’s website at www.lajollapharmaceutical.com.
La Jolla Pharmaceutical Company (LJPC) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option